The abstract is read at the publisher; the summary is JClub's.
Lentivector-mediated HSCT-GT in ACDase-deficient P361R-FD and P361R-SMA mice improves disease manifestations, including lifespan, body weight, and behavioral performance.
- Why it matters: ACDase deficiency causes multi-system organ failure with prominent neurological disease, and there are no approved treatments, leaving a need for effective HSCT-based gene therapy.
- What they did: Using syngeneic cells, the study delivered lentivirus for HSCT-GT in two mouse strains carrying the same AsahI mutation but different background genotypes, then assessed survival, behavior, organ pathology, blood markers, and tissue ceramide.
- The result: The therapy normalized spleen and liver size and pathology, improved peripheral blood characteristics including plasma MCP-1 and IL-6, and reduced histiocytic infiltration and ceramide accumulation in livers and brains.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.